Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir
|
|
- Bryan Gibbs
- 5 years ago
- Views:
Transcription
1 Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir Holly Rawizza 1,2, Regina Oladokun 3, Emeka Ejeliogu 4, Stephen Oguche 4, Oche Agbaji 4, Georgina Odaibo 3, Godwin Imade 4, David Olaleye 3, Kristin Darin 5, Prosper Okonkwo 6, Phyllis Kanki 2, Kimberly Scarsi 7, Helen McIlleron 8 1 Brigham and Women's Hospital, Boston, Massachusetts, USA, 2 Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA, 3 University College Hospital, University of Ibadan, Ibadan, Nigeria, 4 Jos University Teaching Hospital, Jos, Nigeria, 5 Northwestern University School of Professional Studies, Chicago, Illinois, USA, 6 AIDS Prevention Initiative Nigeria (APIN), Ltd., Abuja, Nigeria, 7 University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, USA, 8 University of Cape Town, Cape Town, South Africa Funding: Harvard University Center for AIDS Research (HU CFAR) P30 AI H. Rawizza has no financial relationships with commercial entities to disclose. AIDS Prevention Initiative Nigeria
2 Background For HIV/TB coinfected children who require protease inhibitor (PI)-based antiretroviral therapy (ART), treatment options are lacking Rifampin is a potent inducer of the enzyme cytochrome P450 3A4 and p-glycoprotein, reducing lopinavir (LPV) exposure by approximately 75% when the drugs are given in combination 1 For coinfected children who require LPV/r-based ART, the WHO recommends 2 : (1) Triple nucleoside (3NRTI) regimen; or, (2) Super-boosted LPV/r (i.e. administration of additional ritonavir to provide a 1:1 LPV to ritonavir ratio versus the standard 4:1 LPV/r ratio) Both of these options are suboptimal 1. Bertz R et al. 5 th Int Congress In Drug Ther in HIV, 2000; Abst P WHO, Consolidated guidelines, 2 nd Ed.; Saavedra J et al. 41 st ICAAC, 2001.
3 Background (2) Rifabutin is the preferred rifamycin among adults who require PIs 1 Among children, a dosage of mg/kg daily is recommended for treatment of Mycobacterium avium complex (MAC) disease and TB 2 Only one study has evaluated rifabutin PK and safety among children receiving lopinavir/ritonavir-based ART 3 DSMB stopped study early after 2 of 6 children developed grade 4 neutropenia Among the 6 children in the study, all except one child had AUCs above the target (rifabutin dose: 5 mg/kg thrice weekly) 1. WHO, Consolidated guidelines, 2 nd Ed.; DHHS, Pediatric OI guidelines, 2018; p. U-9, V Moultrie et al. JAC 2014.
4 Methods: Study design and setting Since 2008, APIN began supporting rifabutin access for HIV/TB coinfected adults and children requiring PI-based ART. Rifabutin dosed 2.5 mg/kg daily Retrospective analysis of 42 children revealed favorable safety and efficacy outcomes 1 Prospective pharmacokinetic (PK) study to evaluate rifabutin concentrations and safety among 15 HIV/TB coinfected children 3-15 years of age who require concurrent LPV/rbased ART and rifabutin-containing TB treatment. Received 4-drug anti-tb treatment dosed according to WHO guidelines 1. Rawizza et al. CROI 2015; Abst 940.
5 Enrollment criteria Inclusion criteria: (1) ART-experienced HIV-infected children who are 3-15 years of age and require LPV/r-based ART due to first-line failure; (2) diagnosis of active TB; and, (3) willingness of the parent or legal guardian to provide consent, and child (7-15 years) to provide assent, for participation. Exclusion criteria: (1) baseline labs with evidence of grade 2 or higher abnormalities including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2.5 times the upper limit of the normal (ULN) range for age, creatinine level greater than 2 times the ULN, or an absolute neutrophil count (ANC) less than 800 cells/mm 3 ; (2) receipt of a medication that has drug-drug interactions with LPV/r or rifabutin; or (3) suspected TB meningitis or those presenting with acute respiratory distress or decompensation.
6 Clinical visit schedule Clinical visits and laboratory monitoring occurred 12 times during the study Labs consisted of total WBC count (WBC), calculated absolute neutrophil count (ANC), hemoglobin, platelet count, creatinine, and alanine aminotransferase (ALT) HIV monitoring labs included CD4+ cell count/cd4% and viral load at baseline, then 6- and 12-months Intensive PK study visits occurred 2, 4, and 8 weeks after rifabutin initiation At each of these time points, serial steady-state rifabutin concentrations were measured at pre-dose (0), 2, 4, 8, 12, and 24 hours after the observed dose.
7 Outcomes Efficacy Immunologic and virologic response through 48 weeks TB outcomes through 48 weeks Safety Adverse events (AE) graded based on DAIDS Tables for grading the severity of adult and pediatric AEs (version 2.0; 2014) AEs during rifabutin were at least one grade higher in severity than baseline value PK outcomes Noncompartmental methods were utilized to determine the area under the curve (AUC 0-24 ) for rifabutin and 25-O-desacetyl rifabutin Primary comparator: adults receiving rifabutin 300 mg daily without ART (mean 3.8 g h/ml) 1,2,3 1. Naiker et al. BMC Pharmacol Toxicol 2014;15: Lan et al. PLoS One 2014; 9(1):e Boulanger et al. CID 2009;49:1305.
8 Patient demographics
9 Clinical outcomes
10 Safety summary
11 Individual Laboratory Adverse Events by Severity Grade 3 neutropenia occurred on 3 occasions (4.4%) and resolved despite continuation of rifabutin in all cases Anemia was the most common AE No Grade 3 or 4 abnormalities in platelet count, ALT, Cr No grade 3 or 4 clinical toxicities reported and no discontinuations due to ART or TB medications occurred
12 Rifabutin concentration-time curves: 20 PK visits among 8 patients
13 Rifabutin PK parameters
14 Comparison of rifabutin PK parameters across studies
15 No association between rifabutin AUC-24h and absolute neutrophil count (ANC) Spearman s rho = p= No association between AUC 0-24 and gender, age, weight (kg), body mass index (kg/m 2 ), rifabutin dosage (mg), rifabutin dosage in mg/kg, or PK visit week
16 Summary In children, rifabutin 2.5 mg/kg daily achieved AUC 0-24 comparable to adults. Median rifabutin AUC 0-24 of 4.77 mcg h/ml 3 instances of low rifabutin AUC 0-24, in all cases the values were appropriate at the 4- and 8-week PK visits Favorable HIV and TB outcomes were observed. Overall patients are clinically doing well, with 6 of 7 achieving virologic suppression to <1000 cpm and resolution of TB symptoms at 6 months Rare SAEs Of 407 follow-up laboratory results, Grade 3/4 abnormalities occurred in 11 (3%) and 2 (0.5%) instances, respectively Neutropenia was rare, mild, and improved with ongoing rifabutin therapy
17 Conclusions These data support the use of rifabutin for HIV/TB coinfected children who require LPV/r given the paucity of options for this vulnerable population. Data are limited by age range of patients Future directions Enrollment now complete Additional study underway in young children months
18 Acknowledgements H. McIlleron K. Scarsi R. Oladokun G. Olawoye G. Odaibo D. Olaleye P. Okonkwo All our colleagues at the APIN PEPFAR sites in Nigeria. Most of all, our patients and their caregivers. P. Kanki K. Darin E. Ejeliogu S. Oguche O. Agbaji G. Imade Funding support by HU CFAR P30 AI and HRSA under the terms of Cooperative Agreement #U51HA The contents are solely the responsibility of the authors and do not necessarily represent the official views of the funding institution.
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya Current Challenges of Paediatric HIV Care What is Happening in the
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationPharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria
Abstract no. A-641-0120-07827 Pharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria I.O. Abah 1, P. Ugoagwu, V. Ojeh, L. Ogwuche,
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationGeneric lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085
Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085 Reshmie Ramautarsing, Meena Gorowara, Jasper van der Lugt, Jiratchaya
More informationINTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY
PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationRifabutin for TB for people on ART
Rifabutin for TB for people on ART Reuben Granich WHO HIV/AIDS Department HIV/TB Core Group Meeting Addis Ababa, Ethiopia, 11-12 November 2008 Towards Universal Treatment Access Gains in Access to Care
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationPediatric Patient Information:
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationHIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University Learning objectives Identify the optimal timing of antiretroviral therapy in patients
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationAntiviral Therapy 2012; 17:25 33 (doi: /IMP1915)
Antiviral Therapy 202; 7:25 33 (doi: 0.385/IMP95) Original article Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
More informationPharmacokinetics of lopinavir/ritonavir superboosting in infants and young children co-infected with HIV and TB HIVPED001
Pharmacokinetics of lopinavir/ritonavir superboosting in infants and young children co-infected with HIV and TB HIVPED001 Interim results H RABIE, P DENTI, J LEE, G KINDRA, A COOVADIA, S PILLAY, A LIBERTY,
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationHIV and Malaria Interactions
HIV and Malaria Interactions Dr. Moses R. Kamya Chair and Professor of Medicine Makerere University College of Health Sciences Kampala, Uganda INTEREST, Mombasa, Kenya 8 th -11 th May 2012 1 Outline Brief
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationAIDS Clinical Trials Group A5316
Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception AIDS Clinical Trials Group A5316 Kimberly
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationDELAYS IN INITIATION OF ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED CHILDREN IN RURAL ZAMBIA 9 th Interest Comference Francis H.
DELAYS IN INITIATION OF ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED CHILDREN IN RURAL ZAMBIA 9 th Interest Comference Francis H. Hamangaba Macha Research Trust Zambia Background Care and treatment are available
More informationPhyllis Kanki Principal Investigator Harvard PEPFAR. Institute of Medicine Washington DC January 7, 2010
Data Collection, Outcome/Impact Evaluation and Application for Programmatic and Policy Decisions Phyllis Kanki Principal Investigator Harvard PEPFAR Institute of Medicine Washington DC January 7, 2010
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationFelizarta, Bo Fu, Teresa Ng, Chih-Wei Lin, Federico Mensa Abstract 253. Pibrentasvir (formerly ABT-530) pangenotypic NS3/4A protease inhibitor
ENDURANCE-1: A Phase 3 Evaluation of the Efficacy and Safety of 8- versus 12-week Treatment with Glecaprevir/ Pibrentasvir (formerly ABT-493/ABT-53) in HCV Genotype 1 Infected Patients with or without
More informationRaltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110 Clarke DF, Acosta EP, Chain A, Cababasay M, Wang J, Calabrese K, Spector SA, Bryson
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationVOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008
VOICE Screening Part 1 Visit Operational Walkthrough Johannesburg, South Africa November 2008 Protocol Requirements Administrative, Behavioral, and Regulatory Procedures Informed consent for screening
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationMechanisms of rifamycin-antiretroviral drug interactions
Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors Two previously published
More informationH.6.G.2 Non-MAC Studies
Page 63 H.6.G.2 Non-MAC Studies H.6.G.2.A Non-MAC Studies at the 600 mg dose A 600 mg dose of azithromycin was given in two non-mac studies (354/354A and 167). Please note: Study 354/354A enrolled a mixture
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More information18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa
A Novel Pediatric Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), Nevirapine (NVP): Pharmacokinetics and Safety in HIV-Infected Thai Children 18 July 2009 The 1st International Workshop
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationSafety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to
More informationImmunologic Criteria Are Poor Predictors of Virologic Outcome: Implications for HIV Treatment Monitoring in Resource-Limited Settings
MAJOR ARTICLE HIV/AIDS Immunologic Criteria Are Poor Predictors of Virologic Outcome: Implications for HIV Treatment Monitoring in Resource-Limited Settings Holly E. Rawizza, 1 Beth Chaplin, 2 Seema T.
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationEvaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment
Evaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment Tariro D Chawana MBChB (UZ), MSc Clinical Pharmacology (UZ), DPhil student None Conflict of interest
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationReduced artemether-lumefantrine exposure in HIV-infected Nigerian subjects on nevirapine-based antiretroviral therapy
Reduced artemether-lumefantrine exposure in HIV-infected Nigerian subjects on nevirapine-based antiretroviral therapy FA Fehintola, L Huang, KK Scarsi, KM Darin, GD Morse, OO Akinyinka, FT Aweeka, S Parikh
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationContraceptive Research and Development Organization
COMMONLY USED ABBREVIATIONS AND ACRONYMS IN MTN PROTOCOLS 3TC ACASI AE AIDS ALT ART ARV AST AUC BMD BV CDC cgmp CFR CI CONRAD Cmax Cmin CORE C-PMPA lamivudine audio computer-assisted self interview adverse
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationEffect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community of central Nigeria
Niger J Paed 2014; 41 (1): 1-6 Ebonyi AO Oguche S Dablets E Sumi B Yakubu E Sagay AS ORIGINAL Effect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community
More information43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster H-2013 Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Retrospective Analysis of Over 8,000 Subjects
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThe clinical pharmacology and drug interactions of bedaquiline
7 TH FIDSSA 2017 The clinical pharmacology and drug interactions of bedaquiline Helen McIlleron Division of Clinical Pharmacology University of Cape Town 20 years 2 drugs conditional approval based on
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationThe Genetic Barrier to Resistance
The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013 The Genetic Barrier to Resistance The genetic
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationHyperbilirubinemia during atazanavir treatment in people living with HIV (PLHIV), Sri Lanka. Abstract
Hyperbilirubinemia during atazanavir treatment in people living with HIV (PLHIV), Sri Lanka. D.I.Rajapaksha 1, A.Azraan 2, L.I.Rajapaksa 3 Abstract Introduction: Atazanavir (ATV) is an antiretroviral drug
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationDate of study period: April 12 May 7, 2010 and August September, 2010
Classification of antiretroviral therapy failure using immunologic and clinical versus virologic monitoring in HIV-infected children and adolescents in Cambodia Date of study period: April 12 May 7, 2010
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationDepartment of General Medicine, Juntendo University School of Medicine, Tokyo; and 2
Jpn. J. Infect. Dis., 69, 33 38, 2016 Original Article Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naäƒve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationPAEDIATRIC ANTIRETROVIRAL THERAPY FOR THE GENERAL PRACTITIONER
PAEDIATRIC ANTIRETROVIRAL THERAPY FOR THE GENERAL PRACTITIONER The care of HIV-infected children is somewhat different to that of adults, and although this poses some challenges, it should not impede paediatric
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 15, 2017 Promacta Description Promacta
More informationIndividualized dosing for Jakafi (ruxolitinib)
Individualized dosing for Jakafi (ruxolitinib) Indications and Usage Polycythemia vera Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationBRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS
BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationInformation to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines:
Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: 1. Summary statement of the proposal for inclusion, change or
More information